PortalPublikationenValidation of lymphovascular invasion is an independent prog...

Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy

Standard

Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. / Fajkovic, Harun; Mathieu, Romain; Lucca, Ilaria; Hiess, Manuela; Hübner, Nicolai; Al Hussein Al Awamlh, Bashir; Lee, Richard; Briganti, Alberto; Karakiewicz, Pierre; Lotan, Yair; Roupret, Morgan; Rink, Michael; Kluth, Luis; Loidl, Wolfgang; Seitz, Christian; Klatte, Tobias; Kramer, Gero; Susani, Martin; Shariat, Shahrokh F.

in: UROL ONCOL-SEMIN ORI, Jahrgang 34, Nr. 5, 05.2016, S. 233.e1-6.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Fajkovic, H, Mathieu, R, Lucca, I, Hiess, M, Hübner, N, Al Hussein Al Awamlh, B, Lee, R, Briganti, A, Karakiewicz, P, Lotan, Y, Roupret, M, Rink, M, Kluth, L, Loidl, W, Seitz, C, Klatte, T, Kramer, G, Susani, M & Shariat, SF 2016, 'Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy', UROL ONCOL-SEMIN ORI, Jg. 34, Nr. 5, S. 233.e1-6. https://doi.org/10.1016/j.urolonc.2015.10.013

APA

Fajkovic, H., Mathieu, R., Lucca, I., Hiess, M., Hübner, N., Al Hussein Al Awamlh, B., Lee, R., Briganti, A., Karakiewicz, P., Lotan, Y., Roupret, M., Rink, M., Kluth, L., Loidl, W., Seitz, C., Klatte, T., Kramer, G., Susani, M., & Shariat, S. F. (2016). Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. UROL ONCOL-SEMIN ORI, 34(5), 233.e1-6. https://doi.org/10.1016/j.urolonc.2015.10.013

Vancouver

Fajkovic H, Mathieu R, Lucca I, Hiess M, Hübner N, Al Hussein Al Awamlh B et al. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. UROL ONCOL-SEMIN ORI. 2016 Mai;34(5):233.e1-6. https://doi.org/10.1016/j.urolonc.2015.10.013

Bibtex

@article{e3e6a6e5d6f54dc5b1502e87f46eadae,
title = "Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy",
abstract = "OBJECTIVE: To validate the impact of lymphovascular invasion (LVI) on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) in a large multiinstitutional cohort.MATERIAL AND METHODS: Retrospective data from 6,678 patients treated with a RP and bilateral lymphadenectomy for prostate cancer (PC) from 8 centers were collected. The primary endpoint was BCR.RESULTS: Overall, 767 patients (11.5%) had LVI. Patients with LVI had significantly higher Gleason scores (P = 0.01). After a median follow-up of 28 months (interquartile range: 21-44), patients with LVI had a 1.66 fold increased risk of BCR (P<0.001). The 1-, 2- and 5-year biochemical recurrence-free survival probabilities for LVI vs. no LVI were 94% vs. 97%, 91% vs. 94%, and 76% vs. 84%, respectively. On multivariable analysis that adjusted for the effects of established prognostic factors, LVI was an independent predictor of BCR (hazard ratio = 1.42, P<0.001). Adding LVI to a multivariable base model increased the discrimination by a small but significant margin (+0.2%, P = 0.0005). In subgroup analyses, LVI remained an independent predictor for BCR in patients with worse pathological features.CONCLUSIONS: About 10% of patients with localized PC have LVI on their RP specimen. We confirm that LVI is associated with features of biologic aggressive PC such as high Gleason grade and BCR after RP. Adverse further studies with strict definitions of LVI and longer follow-up periods are needed to determine the prognostic and predictive utility of LVI in the management of PC.",
keywords = "Journal Article",
author = "Harun Fajkovic and Romain Mathieu and Ilaria Lucca and Manuela Hiess and Nicolai H{\"u}bner and {Al Hussein Al Awamlh}, Bashir and Richard Lee and Alberto Briganti and Pierre Karakiewicz and Yair Lotan and Morgan Roupret and Michael Rink and Luis Kluth and Wolfgang Loidl and Christian Seitz and Tobias Klatte and Gero Kramer and Martin Susani and Shariat, {Shahrokh F}",
note = "Copyright {\textcopyright} 2016 Elsevier Inc. All rights reserved.",
year = "2016",
month = may,
doi = "10.1016/j.urolonc.2015.10.013",
language = "English",
volume = "34",
pages = "233.e1--6",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy

AU - Fajkovic, Harun

AU - Mathieu, Romain

AU - Lucca, Ilaria

AU - Hiess, Manuela

AU - Hübner, Nicolai

AU - Al Hussein Al Awamlh, Bashir

AU - Lee, Richard

AU - Briganti, Alberto

AU - Karakiewicz, Pierre

AU - Lotan, Yair

AU - Roupret, Morgan

AU - Rink, Michael

AU - Kluth, Luis

AU - Loidl, Wolfgang

AU - Seitz, Christian

AU - Klatte, Tobias

AU - Kramer, Gero

AU - Susani, Martin

AU - Shariat, Shahrokh F

N1 - Copyright © 2016 Elsevier Inc. All rights reserved.

PY - 2016/5

Y1 - 2016/5

N2 - OBJECTIVE: To validate the impact of lymphovascular invasion (LVI) on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) in a large multiinstitutional cohort.MATERIAL AND METHODS: Retrospective data from 6,678 patients treated with a RP and bilateral lymphadenectomy for prostate cancer (PC) from 8 centers were collected. The primary endpoint was BCR.RESULTS: Overall, 767 patients (11.5%) had LVI. Patients with LVI had significantly higher Gleason scores (P = 0.01). After a median follow-up of 28 months (interquartile range: 21-44), patients with LVI had a 1.66 fold increased risk of BCR (P<0.001). The 1-, 2- and 5-year biochemical recurrence-free survival probabilities for LVI vs. no LVI were 94% vs. 97%, 91% vs. 94%, and 76% vs. 84%, respectively. On multivariable analysis that adjusted for the effects of established prognostic factors, LVI was an independent predictor of BCR (hazard ratio = 1.42, P<0.001). Adding LVI to a multivariable base model increased the discrimination by a small but significant margin (+0.2%, P = 0.0005). In subgroup analyses, LVI remained an independent predictor for BCR in patients with worse pathological features.CONCLUSIONS: About 10% of patients with localized PC have LVI on their RP specimen. We confirm that LVI is associated with features of biologic aggressive PC such as high Gleason grade and BCR after RP. Adverse further studies with strict definitions of LVI and longer follow-up periods are needed to determine the prognostic and predictive utility of LVI in the management of PC.

AB - OBJECTIVE: To validate the impact of lymphovascular invasion (LVI) on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) in a large multiinstitutional cohort.MATERIAL AND METHODS: Retrospective data from 6,678 patients treated with a RP and bilateral lymphadenectomy for prostate cancer (PC) from 8 centers were collected. The primary endpoint was BCR.RESULTS: Overall, 767 patients (11.5%) had LVI. Patients with LVI had significantly higher Gleason scores (P = 0.01). After a median follow-up of 28 months (interquartile range: 21-44), patients with LVI had a 1.66 fold increased risk of BCR (P<0.001). The 1-, 2- and 5-year biochemical recurrence-free survival probabilities for LVI vs. no LVI were 94% vs. 97%, 91% vs. 94%, and 76% vs. 84%, respectively. On multivariable analysis that adjusted for the effects of established prognostic factors, LVI was an independent predictor of BCR (hazard ratio = 1.42, P<0.001). Adding LVI to a multivariable base model increased the discrimination by a small but significant margin (+0.2%, P = 0.0005). In subgroup analyses, LVI remained an independent predictor for BCR in patients with worse pathological features.CONCLUSIONS: About 10% of patients with localized PC have LVI on their RP specimen. We confirm that LVI is associated with features of biologic aggressive PC such as high Gleason grade and BCR after RP. Adverse further studies with strict definitions of LVI and longer follow-up periods are needed to determine the prognostic and predictive utility of LVI in the management of PC.

KW - Journal Article

U2 - 10.1016/j.urolonc.2015.10.013

DO - 10.1016/j.urolonc.2015.10.013

M3 - SCORING: Journal article

C2 - 26973136

VL - 34

SP - 233.e1-6

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 5

ER -